Although we have long known about the existence of microbes—the tiny bacteria, fungi and archaea that live all around us, on us, and in us—interest in how the microbiome might impact human therapeutics has become a hot topic in research only recently.

It is estimated that there are as many as 100 trillion bacteria in the human body. At that number, the human body and its microbiome live in a symbiotic relationship with each other, and it is speculated that one cannot live without the other.

Will future advances in deciphering this paradigm provide hope and revolutionize the healthcare industry of the future and help innovate new ways to control disease and human growth, or is this hype going to unlock a Pandora’s Box of issues, which we understand little about now? 

This white paper, based on a March 2017 web panel discussion, addresses:

  • How will microbiome impact Human Therapeutics? Who’s driving it and why?
  • Is the real way to a person’s heart through their stomach? Maybe the ancients knew!
  • Financial approach and ROI for early and late stage investments into this arena
  • Timelines for impact in terms of developing therapeutics and diagnostics
  • Advances in the sciences needed to “really” understand what’s going on
  • Opportunities and challenges of delving into the human microbiome
  • Where is this field headed in terms of pharma and healthcare involvement?
  • What partnerships are critically needed between academia, companies, financial institutions and the government?
  • Predictions on translation of early successes to therapeutic area
  • FDA and the microbiome – friend or foe?

Read the
white paper